Shilpa Medicare Limited vs Zydus Lifesciences Limited
A side-by-side comparison of Shilpa Medicare Limited (SHILPAMED) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Zydus Lifesciences Limited leads SHILPAMED vs ZYDUSLIFE on 12 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation04
- Profitability04
- Growth01
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
ZYDUSLIFE takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
ZYDUSLIFE takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
ZYDUSLIFE takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
ZYDUSLIFE takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["Stock is trading at 7.08 times its book value", "Company has a low return on equity of 5.1% over last 3 years."]
- + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
- − []
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.